Redaporfin

瑞达泊芬

Report date: 2024/04/10 16:08:25
NME

Base Information

Drug NameRedaporfin
Drug Alias NameredaporfinaredaporfinumLUZ-11F2BMet
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhotosensitizers
TargetsNot applicable
Therapy Area/IndicationsHead and Neck Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPortugal
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBluepharmaUniversity Of Coimbra
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLuzitin Sa
Active IndicationsN/A
Inactive IndicationsHead and Neck Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A